Navigation Links
Rudd Report Highlights AMDL, Inc.'s Latest Business Achievements; Supports 2008 Financial Guidance
Date:8/4/2008

TUSTIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced today that industry analyst Lauren Rudd has posted a second quarter FY2008 corporate update for AMDL, Inc. The full report is available http://www.RuddReport.com and includes a 12 month target price of $23 and Buy Recommendation.

Highlighted within the report are details of AMDL's recent clearance to market by the US FDA for its DR-70(R) blood test for monitoring colorectal cancer, AMDL's FY2008 financial guidance and the Company's top strategic objectives for 2008 and 2009:

-- AMDL's market strategy and distribution plans for DR-70(R), include securing SFDA approval to allow sales and distribution throughout China;

-- The Company's marketing strategy for the MYHPV(R) human papilloma virus Chip Kit;

-- Business expansion details for Jade Pharmaceutical Inc. for FY2008 including growth via new distribution channels and JPGreen Clinics;

-- AMDL's partnership strategy for the Combination Immunogene Therapy (CIT) technology;

-- AMDL's strategic plans for licensing North American drugs for manufacture and sales in China and Asia; and,

-- The Company's goals to secure SFDA approval for new products which will enable AMDL to market and distribute those products throughout China.

This newest Rudd Report also covers a Peer Group Comparison & Valuation Analysis along with views and opinions on AMDL's financial performance for FY2008. Opinions to note include the valuation for DR-70(R) which Mr. Rudd expects to reach approximately $4 million in gross profits during the second half of FY2008 with approximately $3 million in net profits and $0.20 per share in FY2008; and, comments approximating AMDL's net earnings to reach $15.2 million or about $1.01 per share.

According to Mr. Rudd, "AMDL has inherent potential to dramatically increase revenues and profitability in both the United States and China and we believe the Company is one of the most under priced stocks that we've seen in a long time."

The report does not explicitly review AMDL's second quarter 2008 results and the purpose of the interim report is to highlight key business successes that should have already impacted AMDL's share price. A follow-up report will be published once AMDL announced Q2 2008 earnings.

About AMDL: Headquartered in Tustin, CA along with its subsidiary Jade Pharmaceutical Inc. (JPI) with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323

(O) (206) 201-3286


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
2. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
3. CV Therapeutics Reports 2008 Second Quarter Financial Results
4. Gentiva Reports Strong Second Quarter led by Home Health Segment
5. United Therapeutics Reports Second Quarter 2008 Financial Results
6. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
7. Neurocrine Biosciences Reports Second Quarter 2008 Results
8. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
9. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... Ca (PRWEB) , ... January 18, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, was today ... News. The awards program is based entirely on merit and decided upon by ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax┬« personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
Breaking Biology Technology:
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... and Forecasts, 2015 - 2022," projects that the global biometric technology market is expected ... from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced today ... Life Alliance" established by iCarbonX, the ... build a "Global Digital Health Ecosystem that can ... combination of individual,s biological, behavioral and psychological data, ... between the companies, SomaLogic will provide proteomics data ...
Breaking Biology News(10 mins):